Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...

Related Keywords

San Francisco ,California ,United States ,Suzhou ,Jiangsu ,China ,Japan ,Australia ,Singapore ,American ,Daneng Li ,Heinz Josef Lenz ,Professor Department Of Medical Oncology Therapeutics Research ,Translational Science Program ,Merck Co Inc ,Linkedin ,Clinical Research ,Merck Sharp Dohme ,Dynamic Precision Library ,Nasdaq ,Norris Comprehensive Cancer Center ,Adagene Inc ,Twitter ,European Union ,Exchange Commission ,American Society Of Clinical Oncology ,City Of Hope Comprehensive Cancer Center ,American Society ,Clinical Oncology ,Cancers Symposium ,Associate Professor Department ,Medical Oncology ,Therapeutics Research ,Hope Comprehensive Cancer ,Associate Director ,Comprehensive Cancer Center ,Merck Sharp ,